<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835729</url>
  </required_header>
  <id_info>
    <org_study_id>NLG2106</org_study_id>
    <nct_id>NCT02835729</nct_id>
  </id_info>
  <brief_title>A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumos Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the regimen limiting toxicities (RLT) and
      recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving
      remission induction chemotherapy with cytarabine and idarubicin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by development of RLT, AEs and laboratory parameters of indoximod.</measure>
    <time_frame>6 months</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of serum concentrations (Cmax/Steady State) of indoximod freebase and indoximod salt formulation.</measure>
    <time_frame>6 months</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurable Residual Disease Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time on study to induction failure, relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AML patients who become eligible for bone marrow transplantation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum concentrations (Cmax/Steady State)</measure>
    <time_frame>6 months</time_frame>
    <description>Characterize the pharmacokinetics (PK) of indoximod, idarubicin and cytarabine through analysis of blood samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum kynurenine and tryptophan levels</measure>
    <time_frame>2 years</time_frame>
    <description>Characterize the pharmacodynamic (PD) effect of indoximod</description>
  </other_outcome>
  <other_outcome>
    <measure>IDO expression by immunohistochemistry in diagnostic and follow-up bone marrow biopsy specimens</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>IDO protein and mRNA expression in diagnostic and follow-up bone marrow aspirate samples</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Methylation status of the IDO promoter in diagnostic and follow up bone marrow aspiration samples</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b (CLOSED TO ACCRUAL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Phase 1a</arm_group_label>
    <arm_group_label>Phase 1b (CLOSED TO ACCRUAL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Phase 1a</arm_group_label>
    <arm_group_label>Phase 1b (CLOSED TO ACCRUAL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod Freebase</intervention_name>
    <description>IDO pathway inhibitor</description>
    <arm_group_label>Phase 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod HCL F1</intervention_name>
    <description>IDO pathway inhibitor</description>
    <arm_group_label>Phase 1b (CLOSED TO ACCRUAL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod HCL F2</intervention_name>
    <description>IDO pathway inhibitor</description>
    <arm_group_label>Phase 1a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A histologically or pathologically confirmed diagnosis of AML based on WHO
             classification with or without extramedullary disease except for central nervous
             system disease.

          -  ECOG performance status ≤ 2

          -  Left ventricular ejection fraction (LVEF) ≥ 50%

          -  Female patients of childbearing potential must have a negative pregnancy test &lt; 1 week
             prior to enrollment.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients receiving any other investigational agents or immunotherapy

          -  Patients who have received prior chemotherapy for AML with the exception of
             hydroxyurea or leukapheresis for leukocytosis; prior hypomethylating or
             immunomodulatory agents for MDS are allowed

          -  Previous allo-HSCT of any kind

          -  Active, uncontrolled infection including known hepatitis B or C

          -  Active autoimmune disease and chronic inflammatory conditions requiring concurrent use
             of any systemic immunosuppressants or steroids.

          -  History of any other active cancer diagnosis

          -  Pregnant women

          -  Known HIV-infected patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

